Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma

Fumihiko Hirai, Takashi Seto, Eiko Inamasu, Gouji Toyokawa, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Yukito Ichinose

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: The aim of the present study was to retrospectively evaluate the role of S-1-based chemotherapy for patients with relapsed advanced thymic carcinoma (TC). Patients and Methods: This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC. Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression. Results: The patients consisted of 4 males and 4 females with a median age of 59 years (range=41-71); 2 with squamous cell carcinoma, 3 with undifferentiated carcinoma, 1 with poorly-differentiated neuroendocrine carcinoma and 2 not otherwise specified. Grade 3 or higher toxicity was only neutropenia (25.0%). No treatment-related death was observed. The response rate was 50.0% (95% confidence interval (CI)=21.5-78.5%). The median progression free-survival (PFS) and overall survival (OS) of S-1-based chemotherapy were 6.0 and 13.5 months, respectively. Conclusion: S-1-based chemotherapy was found to be potentially useful for patients with relapsed TC.

Original languageEnglish
Pages (from-to)5743-5747
Number of pages5
JournalAnticancer research
Volume34
Issue number10
Publication statusPublished - Oct 1 2014

Fingerprint

Thymoma
Platinum
Drug Therapy
gemcitabine
Neuroendocrine Carcinoma
Neutropenia
Disease-Free Survival
Disease Progression
Squamous Cell Carcinoma
Confidence Intervals
Carcinoma
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hirai, F., Seto, T., Inamasu, E., Toyokawa, G., Yoshida, T., Nosaki, K., ... Ichinose, Y. (2014). Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. Anticancer research, 34(10), 5743-5747.

Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. / Hirai, Fumihiko; Seto, Takashi; Inamasu, Eiko; Toyokawa, Gouji; Yoshida, Tsukihisa; Nosaki, Kaname; Takenaka, Tomoyoshi; Yamaguchi, Masafumi; Takenoyama, Mitsuhiro; Ichinose, Yukito.

In: Anticancer research, Vol. 34, No. 10, 01.10.2014, p. 5743-5747.

Research output: Contribution to journalArticle

Hirai, F, Seto, T, Inamasu, E, Toyokawa, G, Yoshida, T, Nosaki, K, Takenaka, T, Yamaguchi, M, Takenoyama, M & Ichinose, Y 2014, 'Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma', Anticancer research, vol. 34, no. 10, pp. 5743-5747.
Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K et al. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. Anticancer research. 2014 Oct 1;34(10):5743-5747.
Hirai, Fumihiko ; Seto, Takashi ; Inamasu, Eiko ; Toyokawa, Gouji ; Yoshida, Tsukihisa ; Nosaki, Kaname ; Takenaka, Tomoyoshi ; Yamaguchi, Masafumi ; Takenoyama, Mitsuhiro ; Ichinose, Yukito. / Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. In: Anticancer research. 2014 ; Vol. 34, No. 10. pp. 5743-5747.
@article{1a068792ceb14cda980d4a7bd93416a7,
title = "Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma",
abstract = "Aim: The aim of the present study was to retrospectively evaluate the role of S-1-based chemotherapy for patients with relapsed advanced thymic carcinoma (TC). Patients and Methods: This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC. Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression. Results: The patients consisted of 4 males and 4 females with a median age of 59 years (range=41-71); 2 with squamous cell carcinoma, 3 with undifferentiated carcinoma, 1 with poorly-differentiated neuroendocrine carcinoma and 2 not otherwise specified. Grade 3 or higher toxicity was only neutropenia (25.0{\%}). No treatment-related death was observed. The response rate was 50.0{\%} (95{\%} confidence interval (CI)=21.5-78.5{\%}). The median progression free-survival (PFS) and overall survival (OS) of S-1-based chemotherapy were 6.0 and 13.5 months, respectively. Conclusion: S-1-based chemotherapy was found to be potentially useful for patients with relapsed TC.",
author = "Fumihiko Hirai and Takashi Seto and Eiko Inamasu and Gouji Toyokawa and Tsukihisa Yoshida and Kaname Nosaki and Tomoyoshi Takenaka and Masafumi Yamaguchi and Mitsuhiro Takenoyama and Yukito Ichinose",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "34",
pages = "5743--5747",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma

AU - Hirai, Fumihiko

AU - Seto, Takashi

AU - Inamasu, Eiko

AU - Toyokawa, Gouji

AU - Yoshida, Tsukihisa

AU - Nosaki, Kaname

AU - Takenaka, Tomoyoshi

AU - Yamaguchi, Masafumi

AU - Takenoyama, Mitsuhiro

AU - Ichinose, Yukito

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Aim: The aim of the present study was to retrospectively evaluate the role of S-1-based chemotherapy for patients with relapsed advanced thymic carcinoma (TC). Patients and Methods: This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC. Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression. Results: The patients consisted of 4 males and 4 females with a median age of 59 years (range=41-71); 2 with squamous cell carcinoma, 3 with undifferentiated carcinoma, 1 with poorly-differentiated neuroendocrine carcinoma and 2 not otherwise specified. Grade 3 or higher toxicity was only neutropenia (25.0%). No treatment-related death was observed. The response rate was 50.0% (95% confidence interval (CI)=21.5-78.5%). The median progression free-survival (PFS) and overall survival (OS) of S-1-based chemotherapy were 6.0 and 13.5 months, respectively. Conclusion: S-1-based chemotherapy was found to be potentially useful for patients with relapsed TC.

AB - Aim: The aim of the present study was to retrospectively evaluate the role of S-1-based chemotherapy for patients with relapsed advanced thymic carcinoma (TC). Patients and Methods: This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC. Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression. Results: The patients consisted of 4 males and 4 females with a median age of 59 years (range=41-71); 2 with squamous cell carcinoma, 3 with undifferentiated carcinoma, 1 with poorly-differentiated neuroendocrine carcinoma and 2 not otherwise specified. Grade 3 or higher toxicity was only neutropenia (25.0%). No treatment-related death was observed. The response rate was 50.0% (95% confidence interval (CI)=21.5-78.5%). The median progression free-survival (PFS) and overall survival (OS) of S-1-based chemotherapy were 6.0 and 13.5 months, respectively. Conclusion: S-1-based chemotherapy was found to be potentially useful for patients with relapsed TC.

UR - http://www.scopus.com/inward/record.url?scp=84917706025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917706025&partnerID=8YFLogxK

M3 - Article

C2 - 25275083

AN - SCOPUS:84917706025

VL - 34

SP - 5743

EP - 5747

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -